 |
MacDougall Biomedical Communications represents Cambridge-based Momenta Pharmaceuticals as it agrees to be acquired by Johnson & Johnson for $6.5B cash.
It's the biggest pharmaceuticals deal of the year, according to Bloomberg, and the latest sign that drug companies are "looking for ways to bulk up even as the coronavirus pandemic upends other businesses."
Craig Wheeler, CEO of Momenta, called J&J the right company to advance its portfolio of drug candidates for autoimmune and rare diseases.
"J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases, is a strong fit for our company and our portfolio,” he said.
The deal will be completed by the end of the year
MacDougall Biomedical managing director Karen Sharma, a veteran of Schwartz Communications and Newgrange Consulting, represents Momenta.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Have a comment? Send it to 
No comments have been submitted for this story yet.